The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study.
 
Ramez Nassef Eskander
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Clovis Oncology; Daiichi Sankyo/Lilly; Eisai; Merck; Myriad Genetics; Pfizer; Tesaro
Speakers' Bureau - AstraZeneca/MedImmune; Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
 
Naufil Alam
Employment - Amgen; AstraZeneca
Stock and Other Ownership Interests - Amgen; AstraZeneca
Research Funding - Amgen; AstraZeneca
 
Grainne H. Long
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Ozan Ozgoren
Employment - AstraZeneca
Leadership - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Will Ambler
No Relationships to Disclose
 
Stephanie Volpe
Employment - AstraZeneca
Stock and Other Ownership Interests - GlaxoSmithKline
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Alkermes (Inst); Aravive; AstraZeneca; Blueprint Medicines (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); I-Mab (Inst); Immunogen; InxMed (Inst); Merck; Mereo BioPharma; Mereo BioPharma (Inst); Mersana (Inst); Myriad Genetics; Novartis; Onconova Therapeutics; OncXerna Therapeutics; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Forty Seven (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - GOG Partners (Inst)